Biomarkers for Pediatric Pulmonary Arterial Hypertension - a Call to Collaborate

Overview

Journal Front Pediatr

Specialty Pediatrics

Date 2014 Feb 20

PMID 24551834

Citations 15

Authors

Kelley L Colvin

Melanie J Dufva

Ryan P Delaney

D Dunbar Ivy

Kurt R Stenmark

Michael E Yeager

Affiliations

Soon will be listed here.

Abstract

Therapeutic approaches in pediatric pulmonary arterial hypertension (PAH) are based primarily on clinician experience, in contrast to the evidence-based approach in adults with pulmonary hypertension. There is a clear and present need for non-invasive and objective biomarkers to guide the accurate diagnosis, treatment, and prognosis of this disease in children. The multifaceted spectrum of disease, clinical presentation, and association with other diseases makes this a formidable challenge. However, as more progress is being made in the understanding and management of adult PAH, the potential to apply this knowledge to children has never been greater. This review explores the state of the art with regard to non-invasive biomarkers in PAH, with an eye toward those adult PAH biomarkers potentially suitable for application in pediatric PAH.

Citing Articles

Pediatric Pulmonary Hypertension: Definitions, Mechanisms, Diagnosis, and Treatment.

Mukherjee D, Konduri G Compr Physiol. 2021; 11(3):2135-2190.

PMID: 34190343 PMC: 8289457. DOI: 10.1002/cphy.c200023.

Metalloproteinases and their inhibitors are associated with pulmonary arterial stiffness and ventricular function in pediatric pulmonary hypertension.

Schafer M, Ivy D, Nguyen K, Boncella K, Frank B, Morgan G Am J Physiol Heart Circ Physiol. 2021; 321(1):H242-H252.

PMID: 34085841 PMC: 8424580. DOI: 10.1152/ajpheart.00750.2020.

A canonical correlation analysis of the relationship between clinical attributes and patient-specific hemodynamic indices in adult pulmonary hypertension.

Piskin S, Patnaik S, Han D, Bordones A, Murali S, Finol E Med Eng Phys. 2020; 77:1-9.

PMID: 32007361 PMC: 7069525. DOI: 10.1016/j.medengphy.2020.01.006.

New Strategies for the Conduct of Clinical Trials in Pediatric Pulmonary Arterial Hypertension: Outcome of a Multistakeholder Meeting With Patients, Academia, Industry, and Regulators, Held at the European Medicines Agency on Monday, June 12, 2017.

Ollivier C, Sun H, Amchin W, Beghetti M, Berger R, Breitenstein S J Am Heart Assoc. 2019; 8(10):e011306.

PMID: 31088189 PMC: 6585335. DOI: 10.1161/JAHA.118.011306.

Paediatric pulmonary arterial hypertension: updates on definition, classification, diagnostics and management.

Rosenzweig E, Abman S, Adatia I, Beghetti M, Bonnet D, Haworth S Eur Respir J. 2018; 53(1).

PMID: 30545978 PMC: 6351335. DOI: 10.1183/13993003.01916-2018.

References

Nickel N, Kempf T, Tapken H, Tongers J, Laenger F, Lehmann U . Growth differentiation factor-15 in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med. 2008; 178(5):534-41. DOI: 10.1164/rccm.200802-235OC. View

Skoro-Sajer N, Mittermayer F, Panzenboeck A, Bonderman D, Sadushi R, Hitsch R . Asymmetric dimethylarginine is increased in chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med. 2007; 176(11):1154-60. DOI: 10.1164/rccm.200702-278OC. View

Huez S, Vachiery J, Unger P, Brimioulle S, Naeije R . Tissue Doppler imaging evaluation of cardiac adaptation to severe pulmonary hypertension. Am J Cardiol. 2007; 100(9):1473-8. DOI: 10.1016/j.amjcard.2007.06.047. View

Visovatti S, Hyman M, Bouis D, Neubig R, McLaughlin V, Pinsky D . Increased CD39 nucleotidase activity on microparticles from patients with idiopathic pulmonary arterial hypertension. PLoS One. 2012; 7(7):e40829. PMC: 3394716. DOI: 10.1371/journal.pone.0040829. View

Suga K . Pulmonary function-morphologic relationships assessed by SPECT-CT fusion images. Ann Nucl Med. 2012; 26(4):298-310. DOI: 10.1007/s12149-012-0576-5. View

Rao S, Chandak G . Cardiac beriberi: often a missed diagnosis. J Trop Pediatr. 2009; 56(4):284-5. DOI: 10.1093/tropej/fmp108. View

Heresi G, Aytekin M, Hammel J, Wang S, Chatterjee S, Dweik R . Plasma interleukin-6 adds prognostic information in pulmonary arterial hypertension. Eur Respir J. 2013; 43(3):912-4. DOI: 10.1183/09031936.00164713. View

Bernus A, Wagner B, Accurso F, Doran A, Kaess H, Ivy D . Brain natriuretic peptide levels in managing pediatric patients with pulmonary arterial hypertension. Chest. 2008; 135(3):745-751. PMC: 2715554. DOI: 10.1378/chest.08-0187. View

Rupani H, Sanchez-Elsner T, Howarth P . MicroRNAs and respiratory diseases. Eur Respir J. 2012; 41(3):695-705. DOI: 10.1183/09031936.00212011. View

10.

Grothues F, Moon J, Bellenger N, Smith G, Klein H, Pennell D . Interstudy reproducibility of right ventricular volumes, function, and mass with cardiovascular magnetic resonance. Am Heart J. 2004; 147(2):218-23. DOI: 10.1016/j.ahj.2003.10.005. View

11.

Peacock A, Murphy N, McMurray J, Caballero L, Stewart S . An epidemiological study of pulmonary arterial hypertension. Eur Respir J. 2007; 30(1):104-9. DOI: 10.1183/09031936.00092306. View

12.

El-Shanshory M, Badraia I, Donia A, Abd El-Hameed F, Mabrouk M . Asymmetric dimethylarginine levels in children with sickle cell disease and its correlation to tricuspid regurgitant jet velocity. Eur J Haematol. 2013; 91(1):55-61. DOI: 10.1111/ejh.12114. View

13.

Morice A, Pepke-Zaba J, Brown M, Thomas P, Higenbottam T . Atrial natriuretic peptide in primary pulmonary hypertension. Eur Respir J. 1990; 3(8):910-3. View

14.

Amabile N, Guignabert C, Montani D, Yeghiazarians Y, Boulanger C, Humbert M . Cellular microparticles in the pathogenesis of pulmonary hypertension. Eur Respir J. 2012; 42(1):272-9. DOI: 10.1183/09031936.00087212. View

15.

Rabinovitch M . Molecular pathogenesis of pulmonary arterial hypertension. J Clin Invest. 2012; 122(12):4306-13. PMC: 3533531. DOI: 10.1172/JCI60658. View

16.

. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001; 69(3):89-95. DOI: 10.1067/mcp.2001.113989. View

17.

Badesch D, Raskob G, Elliott C, Krichman A, Farber H, Frost A . Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest. 2009; 137(2):376-87. DOI: 10.1378/chest.09-1140. View

18.

Cikach Jr F, Tonelli A, Barnes J, Paschke K, Newman J, Grove D . Breath analysis in pulmonary arterial hypertension. Chest. 2013; 145(3):551-558. PMC: 3941248. DOI: 10.1378/chest.13-1363. View

19.

Paffett M, Hesterman J, Candelaria G, Lucas S, Anderson T, Irwin D . Longitudinal in vivo SPECT/CT imaging reveals morphological changes and cardiopulmonary apoptosis in a rodent model of pulmonary arterial hypertension. PLoS One. 2012; 7(7):e40910. PMC: 3398888. DOI: 10.1371/journal.pone.0040910. View

20.

Yeager M, Nguyen C, Belchenko D, Colvin K, Takatsuki S, Ivy D . Circulating fibrocytes are increased in children and young adults with pulmonary hypertension. Eur Respir J. 2011; 39(1):104-11. PMC: 3319160. DOI: 10.1183/09031936.00072311. View